Pfizer Material Transfer Agreement
The Clinical/Corporate Contracts services team handles both incoming MTAs, where the university receives research materials from other institutions, as well as outgoing MTAs for which we share the university`s research materials with other institutions. The University of Pittsburgh requires that an outgoing MTA (or some other form of contract, for example.B. subcontracting) for university materials be sent by our university. In the coming weeks, BioNTech and Pfizer will finalize the financial conditions and details of how the development, manufacturing and marketing work will work. The implementation of the cooperation agreement means that a joint effort to advance the vaccine will progress in parallel with these discussions. BioNTech believes the vaccine will be tested in humans by the end of next month and already has the capacity to produce materials for the global clinical trial. Partnerships with Fosun and Pfizer are designed to ensure that the program builds momentum to commercial availability. For incoming MTAs (since the owner of the research material determines the conditions under which he wishes to share the material with our university), the PI/PI department should secure the MTA proposed by the owner of the research material Our university is a signatory to the Uniform Biological Material Transfer Agreement (UBMTA), a contractual mechanism published by NIH on behalf of PHS to facilitate the transfer of biological material between academic institutions. For institutions that have accepted the terms of the UBMTA master contract, it is not necessary to negotiate individual terms for any transfer of a biological material.
Instead, a letter of execution is implemented, which refers to both the biological material, the supply agency and the host institution. Where possible, the Clinical/Corporate Contracts Services team will use UBMTA to expedite the transfer of applicable biological materials. Documents signed so far by BioNTech and Pfizer lack details that would normally be at the heart of a co-development agreement, including the final financial terms of the relationship. However, given the rapid increase in the number of COVID-19 cases in countries around the world, Pfizer and BioNTech have decided not to let cooperation stop in the financial details. Material Transfer Agreements (MMA) are contractual documents that are used for the acquisition of various biological and research materials and data sometimes developed by non-profit, public and private companies. Often, these materials are a necessary part of a research project and are only available from a single, often industrial, source. The industry may view its materials as important proprietary resources and assert ownership of inventions made with these materials or limit the publication of adverse results. Universities will want to ensure that the conditions of the MTA allow for the full dissemination of research results and are not at odds with other higher education policies.
Because of these differences of opinion, negotiations to meet the needs of both parties may take time. The usual areas of negotiation are publications, the exploitation of research results and the appropriation of the technology produced by research.